Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Ionis Pharmaceuticals executive Brian Birchler reported several equity transactions. On January 15, 2026, 20,089 shares of common stock were acquired at $0.0 per share upon vesting and release of restricted stock units, increasing his direct holdings to 68,915 shares. On January 16, 2026, he sold 8,480 shares of common stock at a weighted average price of $75.11 per share in an automatic sale to cover tax withholding, leaving 60,435 common shares directly owned.
Birchler also received equity awards on January 15, 2026, including 25,800 Performance Restricted Stock Units (PRSUs), representing the maximum that may be earned based on three‑year relative total shareholder return, and a grant of 9,675 Restricted Stock Units (RSUs). These PRSUs may vest at the end of the three‑year period, while RSUs generally vest in four equal annual installments, each unit representing a right to one share of Ionis common stock or its cash equivalent.
Ionis Pharmaceuticals executive C. Frank Bennett, EVP and Chief Scientific Officer, reported multiple equity transactions. On January 15, 2026, 21,055 shares of common stock were acquired at $0.0 per share through the vesting and release of restricted stock units, increasing his direct common stock holdings to 103,734 shares. On January 16, 2026, he sold 8,977 shares of common stock at a weighted average price of $75.15 per share in an automatic sale to cover tax withholding obligations, leaving 94,757 shares owned directly.
He was also granted 25,800 Performance Restricted Stock Units (PRSUs), representing the maximum that may be earned based on a three-year relative total shareholder return performance period, and 9,675 Restricted Stock Units (RSUs) that vest in four equal annual installments. Each RSU or PRSU represents a contingent right to receive one share of Ionis common stock or its cash equivalent.
Ionis Pharmaceuticals executive Joseph Baroldi reported equity award activity and related share sales. On 01/15/2026, restricted stock units vested, resulting in the acquisition of 17,037 shares of common stock directly and 2,850 shares indirectly through his spouse at an exercise price of $0.0 per share. Following these transactions, he held 47,338 common shares directly and 5,921 shares indirectly through his spouse.
On 01/16/2026, he reported sales of 6,907 directly held shares at a weighted average price of $75.75 and 1,149 indirectly held shares at $75.78, described as automatic sales to cover tax withholding obligations. Separately, on 01/15/2026 he received a grant of 25,800 performance restricted stock units that may vest after a three‑year performance period, as well as additional restricted stock unit grants for himself and his spouse under the company’s equity incentive plan.
Ionis Pharmaceuticals plans an insider share sale under Rule 144. A holder intends to sell 9,884 shares of Ionis common stock through Morgan Stanley Smith Barney, with an approximate sale date of 01/16/2026 on the NASDAQ. The filing notes that 161,137,930 shares of common stock are outstanding.
The 9,884 shares come from restricted stock units granted on 01/15/2026 under the company’s 2011 Equity Incentive Plan, treated as compensation. Over the prior three months, the same account, using Morgan Stanley Smith Barney as seller, sold 23,463 common shares on 01/02/2026 for gross proceeds of $1,856,324.51. The signer represents they are not aware of any undisclosed material adverse information about Ionis.
Ionis Pharmaceuticals has a notice of proposed sale under Rule 144 for 6,999 shares of its common stock. The shares are expected to be sold on or about 01/16/2026 through broker Morgan Stanley Smith Barney on the NASDAQ market, with an aggregate market value of $559,920. The filing notes that these shares were acquired on 01/15/2026 as restricted stock units granted under the company’s 2011 Equity Incentive Plan and delivered as compensation. The filing also reports that 161,974,393 shares of Ionis common stock were outstanding, providing context for the planned sale size.
Ionis Pharmaceuticals has a planned insider sale disclosed through a Rule 144 notice. The filing covers the potential sale of 8,977 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an aggregate market value of $684,263.90. These shares were acquired on 01/15/2026 as restricted stock units granted under the company’s 2011 Equity Incentive Plan and classified as compensation. The planned sale date is approximately 01/16/2026. The filing also notes that 161,137,930 shares of Ionis common stock were outstanding, providing context for the size of this transaction.
Ionis Pharmaceuticals has a planned insider sale of 8,480 shares of its common stock under Rule 144. The shares are expected to be sold through Morgan Stanley Smith Barney on or about January 16, 2026, with an aggregate market value of $646,375.84, on the NASDAQ exchange.
The securities were acquired on January 15, 2026 as RSUs granted under the company’s 2011 Equity Incentive Plan, classified as compensation. The filing notes that 161,137,930 shares of common stock were outstanding, giving context for the size of this planned transaction.
Ionis Pharmaceuticals has a holder filing a notice of proposed sale of 12,922 shares of common stock, with an aggregate market value of $985,108.70. The shares are expected to be sold through Morgan Stanley Smith Barney on the NASDAQ around 01/16/2026. Ionis common shares outstanding were 161,137,930 at the time referenced. The seller acquired these 12,922 shares on 01/15/2026 as performance stock units granted under the company’s 2011 Equity Incentive Plan, treated as compensation.
Ionis Pharmaceuticals is the issuer of common stock that a holder plans to sell under Rule 144. The notice covers the planned sale of 44,034 shares of common stock through Morgan Stanley Smith Barney on or about 01/16/2026 on the NASDAQ market, with an aggregate market value of $3,357,167.26. These shares were acquired on 01/15/2026 as RSUs granted under the 2011 Equity Incentive Plan, treated as compensation. As context, 161,137,930 shares of this class were outstanding at the time stated.
Ionis Pharmaceuticals has a planned insider sale of common stock reported under Rule 144. The filing covers the potential sale of 4,141 shares of Ionis common stock through broker Morgan Stanley Smith Barney, with an aggregate market value of $315,484.80. The notice lists total common shares outstanding as 161,137,930 and identifies NASDAQ as the exchange where the shares are to be sold. The securities were acquired as RSUs granted under the 2011 Equity Incentive Plan and treated as compensation.